Samsung Bioepis and Takeda enter biologics co-development deal; Takeda opts out of deal
Samsung Bioepis Co. Ltd., a joint venture formed by Samsung BioLogics and Biogen Inc., and Takeda Pharmaceutical Co. Ltd. entered an agreement to co-fund and co-develop biologics for diseases of unmet need.
- Large Molecule
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com